JP Morgan Chase
KYNB

JP Morgan Chase’s Kyntra Bio KYNB Stock Holding History

JP Morgan Chase’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,000
Closed -$3.71M – 6147
2020
Q4 		$3.71M Buy
+4,000
New +$4.2M ﹤0.01% 3040

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

JP Morgan Chase's KYNB Position: Q2 2026 in Review

JP Morgan Chase held its Kyntra Bio (KYNB) position steady in Q2 2026 at 12 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #7546.

JP Morgan Chase first reported a position in KYNB in Q4 2014 and has held it in 47 quarters since. The position peaked at $80.3M in Q3 2020. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • JP Morgan Chase held 12 shares of Kyntra Bio worth $88 as of Q2 2026.
  • JP Morgan Chase left its Kyntra Bio share count unchanged in Q2 2026.
  • Kyntra Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7546 holding.
  • JP Morgan Chase first reported a position in Kyntra Bio in Q4 2014 and has held it in 47 quarters since.
  • JP Morgan Chase's Kyntra Bio position peaked at $80.3M in Q3 2020.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.